The present study demonstrated that EECM treatment significantly ameliorates the symptoms of postmenopausal osteoporosis in vivo, by promoting osteoblast differentiation by the induction of BMP2-MAPK-Runx2 signaling, and subsequently by indirect suppression of osteoclastogenesis by OPG. This evidence concerns the gene RUNX2 and postmenopausal osteoporosis.